These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 36179498)
21. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability. Zhang X; Zhang T; Lan Y; Wu B; Shi Z AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778 [TBL] [Abstract][Full Text] [Related]
22. Exploitation of nanocrystal suspension as an effective oral formulation for oxfendazole. Sun Y; Chen D; Zhao Y; Zhou K; Zhang B; Wang H; Xie S Drug Deliv Transl Res; 2022 May; 12(5):1219-1229. PubMed ID: 34148210 [TBL] [Abstract][Full Text] [Related]
23. Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor. Na YG; Pham TMA; Byeon JJ; Kim MK; Han MG; Baek JS; Lee HK; Cho CW Int J Pharm; 2020 May; 581():119287. PubMed ID: 32243963 [TBL] [Abstract][Full Text] [Related]
24. Improved oral bioavailability of core-shell structured beads by redispersion of the shell-forming nanoparticles: preparation, characterization and in vivo studies. Yao Q; Tao X; Tian B; Tang Y; Shao Y; Kou L; Gou J; Li X; Yin T; Tang X Colloids Surf B Biointerfaces; 2014 Jan; 113():92-100. PubMed ID: 24060933 [TBL] [Abstract][Full Text] [Related]
25. Fabrication of Stable Apigenin Nanosuspension with PEG 400 as Antisolvent for Enhancing the Solubility and Bioavailability. Xu R; Jiang C; Zhou L; Li B; Hu Y; Guo Y; Xiao X; Lu S AAPS PharmSciTech; 2021 Dec; 23(1):12. PubMed ID: 34881399 [TBL] [Abstract][Full Text] [Related]
26. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs. Elsebay MT; Eissa NG; Balata GF; Kamal MA; Elnahas HM Curr Pharm Des; 2023; 29(29):2297-2312. PubMed ID: 37694786 [TBL] [Abstract][Full Text] [Related]
27. Preparation and in vitro / in vivo evaluation of flurbiprofen nanosuspension-based gel for dermal application. Oktay AN; Ilbasmis-Tamer S; Han S; Uludag O; Celebi N Eur J Pharm Sci; 2020 Dec; 155():105548. PubMed ID: 32937211 [TBL] [Abstract][Full Text] [Related]
28. Improving abamectin bioavailability via nanosuspension constructed by wet milling technique. Cui B; Lv Y; Gao F; Wang C; Zeng Z; Wang Y; Sun C; Zhao X; Shen Y; Liu G; Cui H Pest Manag Sci; 2019 Oct; 75(10):2756-2764. PubMed ID: 30859694 [TBL] [Abstract][Full Text] [Related]
29. Jejunal absorption of aprepitant from nanosuspensions: Role of particle size, prandial state and mucus layer. Roos C; Dahlgren D; Sjögren E; Sjöblom M; Hedeland M; Lennernäs H Eur J Pharm Biopharm; 2018 Nov; 132():222-230. PubMed ID: 30266667 [TBL] [Abstract][Full Text] [Related]
30. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability. Parmar K; Shah J Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540 [TBL] [Abstract][Full Text] [Related]
31. Preparation, characterization and pharmacokinetics of cyadox nanosuspension. Sattar A; Chen D; Jiang L; Pan Y; Tao Y; Huang L; Liu Z; Xie S; Yuan Z Sci Rep; 2017 May; 7(1):2289. PubMed ID: 28536446 [TBL] [Abstract][Full Text] [Related]
32. Production, Characterization and Evaluation of Kaempferol Nanosuspension for Improving Oral Bioavailability. Qian YS; Ramamurthy S; Candasamy M; Shadab M; Kumar RH; Meka VS Curr Pharm Biotechnol; 2016; 17(6):549-55. PubMed ID: 26813303 [TBL] [Abstract][Full Text] [Related]
33. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation. Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490 [TBL] [Abstract][Full Text] [Related]
34. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability. Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174 [TBL] [Abstract][Full Text] [Related]
35. Fabrication of amorphous curcumin nanosuspensions using β-lactoglobulin to enhance solubility, stability, and bioavailability. Aditya NP; Yang H; Kim S; Ko S Colloids Surf B Biointerfaces; 2015 Mar; 127():114-21. PubMed ID: 25660094 [TBL] [Abstract][Full Text] [Related]
36. Recent Advances in Nanosuspension Technology for Drug Delivery. Arora D; Khurana B; Rath G; Nanda S; Goyal AK Curr Pharm Des; 2018; 24(21):2403-2415. PubMed ID: 29788880 [TBL] [Abstract][Full Text] [Related]
37. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension. Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096 [TBL] [Abstract][Full Text] [Related]
38. Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process. Kalvakuntla S; Deshpande M; Attari Z; Kunnatur B K Adv Pharm Bull; 2016 Mar; 6(1):83-90. PubMed ID: 27123422 [TBL] [Abstract][Full Text] [Related]
39. Quality by design-based optimization of formulation and process parameters for berberine nanosuspension for enhancing its dissolution rate, bioavailability, and cardioprotective activity. Alsabeelah N; Kumar V J Food Biochem; 2022 Oct; 46(10):e14361. PubMed ID: 35929374 [TBL] [Abstract][Full Text] [Related]
40. Diclofenac acid nanocrystals as an effective strategy to reduce in vivo skin inflammation by improving dermal drug bioavailability. Pireddu R; Caddeo C; Valenti D; Marongiu F; Scano A; Ennas G; Lai F; Fadda AM; Sinico C Colloids Surf B Biointerfaces; 2016 Jul; 143():64-70. PubMed ID: 26998867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]